



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/445, 9/08		A1	(11) International Publication Number: WO 99/25349
(21) International Application Number: PCT/GB98/03479		(43) International Publication Date: 27 May 1999 (27.05.99)	
(22) International Filing Date: 19 November 1998 (19.11.98)		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 9724506.2 19 November 1997 (19.11.97) GB 9818109.2 19 August 1998 (19.08.98) GB		(71) Applicant: DARWIN DISCOVERY LIMITED [GB/GB]; Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB).	
(72) Inventor: BROWN, Stephen; Darwin Discovery Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB).		(74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).	
<p>(54) Title: ANAESTHETIC FORMULATION</p> <p>(57) Abstract</p> <p>A pharmaceutically acceptable aqueous solution which is isobaric or hyperbaric, and isotonic, with respect to cerebrospinal fluid (CSF), comprises a 1-alkyl-N-(2,6-dimethylphenyl)-2-piperidinocarboxamide anaesthetic agent such as bupivacaine or levobupivacaine and a saccharide. If the amount of the anaesthetic agent is no more than 0.75 % w/v, a salt or another additional non-saccharide is present. Accordingly, the amount of the saccharide can be kept below that which would provide isotonicity in the absence of the additional non-saccharide.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

ANAESTHETIC FORMULATIONField of the Invention

This invention relates to a new formulation of long-acting local anaesthetics.

Background of the Invention

5 A known class of long-acting local anaesthetics comprises 1-alkyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamides. This class includes racemic bupivacaine, levobupivacaine, mepivacaine and ropivacaine. Racemic bupivacaine is widely used, and is available for both epidural and spinal administration.

10 The effective utility of levobupivacaine in man, *in vivo*, is evidenced for the first time in WO-A-9510276, WO-A-9510277 and Gristwood *et al*, *Exp. Opin. Invest. Drugs* 3(11):1209-12 (1994). The latter documents indicate the potential utility of levobupivacaine in obstetrics, in part at least because of reduced CNS side-effects.

15 WO 90/00390 discloses aqueous solutions for spinal analgesia, comprising dezocine, bupivacaine and also 5-10% w/v glucose if it is desired that the solution should be hyperbaric. The solutions of the Examples which are hyperbaric are also hypertonic.

Chung *et al*, *Br. J. Anaesth.* (1996) 77(2):145-9, discloses the use of hyperbaric solutions containing 0.25% w/v bupivacaine and 5% w/v glucose, for spinal anaesthesia. This was done as part of a study to determine the effect of volume of solution administered.

20 Hytta *et al*, *Regionale-Anaesthesia* (1982) 5:85-8, discloses the use of 0.5% bupivacaine, either "isobaric" (Marcain®) or hyperbaric (8% glucose). The former is presumably plain Marcain® which is in fact hypobaric.

25 In the US, a hyperbaric formulation of bupivacaine is available, comprising 2 ml ampoules of 0.75% bupivacaine (racemate) and 8.25% glucose. The use of 0.75% solutions of racemic bupivacaine is contra-indicated, in obstetrical anaesthesia. The Physician's Desk Reference® carries a "black box" warning.

In Europe, 4 ml ampoules are available which contain 0.5% bupivacaine and about 8% glucose. These formulations are hypertonic, having an osmolality of approximately 500 mOsm/kg.

30 There are certainly good reasons for including glucose. As reported by Logan *et al*, *Brit. J. Anaesthesia* (1986) 58:292-296, plain 0.5% bupivacaine has wide variability in terms of its intrathecal spread, when administered for spinal anaesthesia. A hyperbaric

solution containing 8% glucose spreads rapidly but predictably; see Chambers *et al*, Brit. J. Anaesthesia (1981) 53:279-282.

5 Bannister *et al*, Brit. J. Anaesthesia (1990) 64:232-234, reports the effects of intrathecal injection of 0.5% bupivacaine in solutions containing 0.33%, 0.83% or 8% glucose. It is suggested that, whereas using 0.33% glucose resulted in variable blocks, as seen using the plain solution, 0.83% glucose is preferable. It is reported that "Making bupivacaine slightly hyperbaric seemed to produce a predictable spinal anaesthetic"; however, formulations comprising 0.5% bupivacaine and 0.83% glucose are in fact hypobaric.

10 It has apparently been accepted by anaesthetists that a high concentration of glucose is necessary. This is despite the fact that such formulations have been associated with neurotoxicity.

Summary of the Invention

15 This invention is based at least in part on the realisation that, in order for a formulation of bupivacaine to be most useful for spinal administration, i.e. at least isobaric and also isotonic with respect to cerebrospinal fluid (CSF), the level of saccharide should be chosen with relation to the amount of bupivacaine, and should be in a range between those previously suggested. The ability to produce an isotonic formulation means that potential exchange of solutes with the cellular material in CSF 20 is avoided.

25 Investigation of various solutions of levobupivacaine, has shown that, at relatively high concentrations and on the addition of glucose, the total amount of the two compounds alone may be sufficient to provide isotonicity. More particularly, at above 0.75%, the level of glucose can be below 5% w/v, while still providing isobaricity or hyperbaricity. When the concentration of the anaesthetic is lower, the inclusion of an additional non-saccharide compound allows the same combination of parameters to be achieved.

30 According to the present invention, the beneficial effects of a 1-alkyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide such as bupivacaine can be provided in combination with a relatively small amount of glucose and, if necessary, a salt such as NaCl. The glucose provides adequate baricity, whilst the salt makes the composition isotonic. The use of large amounts of glucose is thus avoided, and the risk associated with contact between the composition and plasma or cerebrospinal fluid is reduced.

Description of the Invention

A solution of the invention will usually be sterile, and typically comprises up to 1% w/v of the anaesthetic, e.g. at least 0.25%, and often 0.5 to 0.75% w/v. An advantage of the use of levobupivacaine over bupivacaine may be the ability to use higher 5 concentrations.

Preferably, a composition of the invention is made up in unit dosages, e.g. of 2 or 3 ml, suitably in a sealed container, e.g. of glass or a transparent plastics material. One preferred formulation comprises 2 ml ampoules or vials of 0.75% levobupivacaine (this compound is described herein for the purposes of illustration only).

10 Spinal administration may be by any conventional means. The formulation will generally be given to provide anaesthesia and analgesia during surgical procedures and also in Caesarean section and to treat chronic pain.

15 Levobupivacaine used in the present invention is preferably substantially free of dextrobupivacaine, and is more preferably in at least 90%, and most preferably at least 99%, enantiomeric excess with respect to dextrobupivacaine. Throughout this specification, reference to bupivacaine and its enantiomers includes pharmaceutically-acceptable salts thereof. Such a compound is typically provided as the HCl salt. Any other salt that is present must of course be physiologically-acceptable, and will usually comprise an inorganic cation. For example, it may be an alkali metal salt such as NaCl.

20 The administration of levobupivacaine over a range of concentrations, including those currently used for the racemic drug and higher concentrations, can be carried out for significantly longer periods than at present, again as a result of the reduced side-effects experienced with levobupivacaine. For instance, levobupivacaine can be administered to a patient safely for at least 24 hours, often up to 72 hours, and even for 25 periods of up to a week or a fortnight, or longer. It can, of course, be administered for similar periods already used for the racemic drug, e.g. between 3 and 6 hours.

The following Examples illustrate the invention. These Examples use levobupivacaine; using bupivacaine instead should have no effect on osmolality or baricity, at equimolar concentrations.

Example 1

Various aqueous formulations of levobupivacaine ("levo") and dextrose were made. They and their baricity and tonicity (and also the corresponding values for CSF) are given in the following Table.

	Product	Specific Gravity	Osmolality (mOsm/kg)
5	CSF	1.0062-1.0082	306
	0.75% Levo + 0 dextrose	1.001	46
10	0.75% Levo + 2.2% dextrose	1.0082	170
	0.75% Levo + 8.25% dextrose	1.029	510
	0.5% Levo + 0 dextrose	1.000	32
15	0.5% Levo + 2.5% dextrose	1.0082	168
	0.5% Levo + 8.25% dextrose	1.028	488

20 Formulations containing more than 2.2% dextrose with 0.75% (7.5 mg/ml) levobupivacaine, or more than 2.5% dextrose with 0.5% (5.0 mg/ml) levobupivacaine, will be technically hyperbaric in all patients. Such formulations, containing less than 5% dextrose, are hypo-osmolar; a suitable salt (NaCl) is added to make the formulations isotonic.

Example 2

An aqueous formulation was prepared comprising 0.5% or 0.75% w/v levobupivacaine, 4% w/v dextrose and 0.15% NaCl. This was an isotonic, hyperbaric composition suitable for spinal administration, to provide safe, effective anaesthesia.

25 In summary, it has been shown that it is possible to reduce the level of glucose in the formulation whilst maintaining an appropriate degree of baricity. Also by the addition of physiologically-acceptable inorganic salts such as sodium chloride, an osmotically-balanced formulation which is isotonic with CSF and body fluids (approximating to 300 mOsm/kg) has been achieved.

CLAIMS

1. A pharmaceutically-acceptable aqueous solution which is isobaric or hyperbaric, and isotonic, with respect to cerebrospinal fluid (CSF), and which comprises a 1-alkyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide anaesthetic agent and a saccharide, 5 provided that, if the amount of the anaesthetic agent is no more than 0.75% w/v, an additional non-saccharide is present and the amount of the saccharide is below that which would provide isotonicity in the absence of the additional non-saccharide.
2. A solution according to claim 1, which comprises up to 1% w/v of the anaesthetic agent.
- 10 3. A composition according to claim 1 or claim 2, which comprises more than 0.75% w/v of the anaesthetic agent, and the non-saccharide is absent.
4. A composition according to claim 1, which comprises up to 0.75% w/v of the anaesthetic agent.
- 15 5. A solution according to claim 4, which comprises 0.5 to 0.75% w/v of the anaesthetic agent.
6. A solution according to any preceding claim, wherein the saccharide is glucose.
7. A solution according to any preceding claim, which comprises more than 1% w/w of the saccharide.
- 18 8. A solution according to claim 7, which comprises more than 2% w/w of the saccharide.
9. A solution according to any preceding claim, wherein the non-saccharide is present and is a salt comprising an inorganic cation.
10. A solution according to claim 9, wherein the salt is NaCl.
11. A solution according to any preceding claim, which is hyperbaric with respect to 25 CSF.
12. A solution according to any preceding claim, wherein the alkyl group has 1 to 4 C atoms.
13. A solution according to claim 12, wherein the anaesthetic agent is bupivacaine.
14. A composition according to claim 12, wherein the anaesthetic agent is 30 levobupivacaine.
15. A container containing a sterile solution according to any preceding claim.

INTERNATIONAL SEARCH REPORT

I. National Application No

PCT/GB 98/03479

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/445 A61K9/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^o	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 90 00390 A (ASTRA) 25 January 1990 cited in the application see page 2, line 13 - line 14 see claims 1,2,4-7 see examples see page 3, line 12 - line 15 see page 3, line 31 - line 32</p> <p>---</p> <p style="text-align: center;">-/--</p>	1-13

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

^o Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search 16 February 1999	Date of mailing of the international search report 22/02/1999
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Scarpioni, U

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/03479

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CHEMICAL ABSTRACTS, vol. 127, no. 21, 24 November 1997 Columbus, Ohio, US; abstract no. 287549, XP002079494 see abstract & M. L. DE PAULA ET AL.: "SUBARACHNOID DISPERSION OF LOCAL ANESTHETICS:CONSIDERATION IN FACE OF THE ADVENT OF ISOBARIC BUPIVACAINE" REV. BRAS. ANESTESIOL., vol. 47, no. 5, 1997, pages 439-452, ---</p>	1,6-8, 11-13
X	<p>CHEMICAL ABSTRACTS, vol. 125, no. 5, 29 July 1996 Columbus, Ohio, US; abstract no. 49134, XP002079496 see abstract & E. M. GANEM ET AL.: "NEUROTOXICITY OF SUBARACHNOID HYPERBARIC BUPIVACAINE IN DOGS" REG. ANESTH., vol. 21, no. 3, 1996, pages 234-238, ---</p>	1-3,6-8, 11-13
Y	<p>CHEMICAL ABSTRACTS, vol. 125, no. 15, 7 October 1996 Columbus, Ohio, US; abstract no. 185717, XP002079495 cited in the application see abstract & C.J.CHANG ET AL.: "SPINAL ANESTESIA WITH 0.25% HYPERBARIC BUPIVACAINE FOR CESAREAN SECTION:EFFECTS OF VOLUME" BR. J. ANAESTH., vol. 77, no. 2, 1996, pages 145-149, ---</p>	1-15
Y	<p>CHEMICAL ABSTRACTS, vol. 124, no. 23, 3 June 1996 Columbus, Ohio, US; abstract no. 307201, XP002079497 see abstract & K.F. HAMPL ET AL.: "HYPEROSMOLARITY DOES NOT CONTRIBUTE TO TRANSIENT RADICULAR IRRITATION AFTER SPINAL ANESTHESIA WITH HYPERBARIC 5% LIDOCAINE" REG. ANESTH., vol. 20, no. 5, 1995, pages 363-368, ---</p>	1-15
		-/-

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 98/03479

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>CHEMICAL ABSTRACTS, vol. 124, no. 21, 20 May 1996 Columbus, Ohio, US; abstract no. 278937, XP002079498 see abstract & J.E. TETZLAFF ET AL.: "INFLUENCE OF BARICITY ON THE OUTCOME OF SPINAL ANESTHESIA WITH BUPIVACAINE FOR LUMBAR SPINE SURGERY" REG. ANESTH., vol. 20, no. 6, 1995, pages 533-537, ---</p>	1-15
Y	<p>CHEMICAL ABSTRACTS, vol. 106, no. 14, 6 April 1987 Columbus, Ohio, US; abstract no. 107814, XP002079499 see abstract & D. BIGLER ET AL.: "DOUBLE-BLIND EVALUATION OF INTRATHECAL HYPERBARIC AND GLUCOSE-FREE BUPIVACAINE ON ANALGESIA AND CARDIOVASCULAR FUNCTION" REG. ANESTH., vol. 11, no. 4, 1986, pages 151-155, ---</p>	1-15
Y	<p>CHEMICAL ABSTRACTS, vol. 98, no. 7, 14 February 1983 Columbus, Ohio, US; abstract no. 46867, XP002079500 cited in the application see abstract & J. KYTTA ET AL.: "HISTOPATHOLOGICAL CHANGES IN RABBIT SPINAL CORD CAUSED BY BUPIVACAINE" REG. ANAESTH., vol. 5, no. 4, 1982, pages 85-88, ---</p>	1-15
A	<p>WO 95 10276 A (CHIROSCIENCE) 20 April 1995 cited in the application see claims see page 3, line 12 - line 25 ---</p>	1-15
A	<p>WO 95 10277 A (CHIROSCIENCE) 20 April 1995 cited in the application see claims see page 3, line 5 - line 13 -----</p>	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/03479

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9000390	A 25-01-1990	AU 3856489	A	05-02-1990
WO 9510276	A 20-04-1995	AT 154758	T	15-07-1997
		AT 150643	T	15-04-1997
		AU 700902	B	14-01-1999
		AU 5183098	A	12-03-1998
		AU 692477	B	11-06-1998
		AU 7859394	A	04-05-1995
		AU 694453	B	23-07-1998
		AU 7859494	A	04-05-1995
		CA 2173207	A	20-04-1995
		CN 1133009	A	09-10-1996
		CN 1133010	A	09-10-1996
		DE 69402330	D	30-04-1997
		DE 69402330	T	03-07-1997
		DE 69403969	D	31-07-1997
		DE 69403969	T	20-11-1997
		DK 723444	T	29-12-1997
		DK 723445	T	06-10-1997
		EP 0723444	A	31-07-1996
		EP 0723445	A	31-07-1996
		EP 0727210	A	21-08-1996
		ES 2105766	T	16-10-1997
		ES 2101578	T	01-07-1997
		WO 9510277	A	20-04-1995
		GR 3023289	T	30-07-1997
		GR 3024787	T	30-01-1998
		JP 9503777	T	15-04-1997
		JP 9503778	T	15-04-1997
		NO 961478	A	11-06-1996
		NO 961479	A	11-06-1996
		US 5849763	A	15-12-1998
		US 5708011	A	13-01-1998
WO 9510277	A 20-04-1995	AT 154758	T	15-07-1997
		AT 150643	T	15-04-1997
		AU 700902	B	14-01-1999
		AU 5183098	A	12-03-1998
		AU 692477	B	11-06-1998
		AU 7859394	A	04-05-1995
		AU 694453	B	23-07-1998
		AU 7859494	A	04-05-1995
		CA 2173207	A	20-04-1995
		CN 1133009	A	09-10-1996
		CN 1133010	A	09-10-1996
		DE 69402330	D	30-04-1997
		DE 69402330	T	03-07-1997
		DE 69403969	D	31-07-1997
		DE 69403969	T	20-11-1997
		DK 723444	T	29-12-1997
		DK 723445	T	06-10-1997
		EP 0723444	A	31-07-1996
		EP 0723445	A	31-07-1996
		EP 0727210	A	21-08-1996
		ES 2105766	T	16-10-1997
		ES 2101578	T	01-07-1997
		WO 9510276	A	20-04-1995
		GR 3023289	T	30-07-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/03479

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9510277 A		GR 3024787 T	30-01-1998
		JP 9503777 T	15-04-1997
		JP 9503778 T	15-04-1997
		NO 961478 A	11-06-1996
		NO 961479 A	11-06-1996
		US 5849763 A	15-12-1998
		US 5708011 A	13-01-1998